Tolterodine-a new bladder selective muscarinic receptor antagonist: Preclinical pharmacological and clinical data
References (26)
- et al.
Life Sci
(1995) - et al.
TIPS
(1994) Pharmacol. Rev.
(1993)- et al.
J.Pharmacol. Exp.Ther.
(1995) - et al.
Drugs Aging
(1995) - et al.
Neurourol.Urodyn.
(1994) - et al.
Neurourol Urodyn
(1995) - et al.
Neurourol. Urodyn
(1996) - et al.
Neurourol. Urodyn.
(1996)
Neurourol. Urodyn.
(1995)
J. Pharmacol. Exp. Ther.
(1991)
Br. J. Pharmacol.
(1991)
Cited by (204)
The muscarinic receptor antagonist tolterodine inhibits voltage-dependent K<sup>+</sup> channels in rabbit coronary arterial smooth muscle cells
2020, European Journal of PharmacologyTolterodine Tartrate
2017, Profiles of Drug Substances, Excipients and Related MethodologyCitation Excerpt :(R)-Tolterodine l-tartrate belongs to the family of muscarinic receptor antagonists and is indicated for the treatment of overactive urinary bladder (OAB) syndrome [1].
Design of hydrogels of 5-hydroxymethyl tolterodine and their studies on pharmacokinetics, pharmacodynamics and transdermal mechanism
2017, European Journal of Pharmaceutical SciencesPharmacokinetic drug interaction study between overactive bladder drugs mirabegron and tolterodine in Japanese healthy postmenopausal females
2016, Drug Metabolism and PharmacokineticsUrinary incontinence in geriatric patients: Diagnosis and therapy
2023, Aktuelle UrologieCurrent and Emerging Pharmacological Targets and Treatments of Urinary Incontinence and Related Disorders
2023, Pharmacological Reviews
Copyright © 1997 Published by Elsevier Inc.